JP2021515558A5 - - Google Patents
Info
- Publication number
- JP2021515558A5 JP2021515558A5 JP2020546854A JP2020546854A JP2021515558A5 JP 2021515558 A5 JP2021515558 A5 JP 2021515558A5 JP 2020546854 A JP2020546854 A JP 2020546854A JP 2020546854 A JP2020546854 A JP 2020546854A JP 2021515558 A5 JP2021515558 A5 JP 2021515558A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- region
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023172758A JP2023168545A (ja) | 2018-03-09 | 2023-10-04 | 二量体抗原受容体（ｄａｒ） |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862640775P | 2018-03-09 | 2018-03-09 | |
| US62/640,775 | 2018-03-09 | ||
| PCT/US2019/021681 WO2019173837A1 (en) | 2018-03-09 | 2019-03-11 | Dimeric antigen receptors (dar) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023172758A Division JP2023168545A (ja) | 2018-03-09 | 2023-10-04 | 二量体抗原受容体（ｄａｒ） |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021515558A JP2021515558A (ja) | 2021-06-24 |
| JP2021515558A5 true JP2021515558A5 (https=) | 2022-03-04 |
| JP7542439B2 JP7542439B2 (ja) | 2024-08-30 |
Family
ID=67846344
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546854A Active JP7542439B2 (ja) | 2018-03-09 | 2019-03-11 | 二量体抗原受容体（ｄａｒ） |
| JP2023172758A Pending JP2023168545A (ja) | 2018-03-09 | 2023-10-04 | 二量体抗原受容体（ｄａｒ） |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023172758A Pending JP2023168545A (ja) | 2018-03-09 | 2023-10-04 | 二量体抗原受容体（ｄａｒ） |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12180294B2 (https=) |
| EP (1) | EP3762430A4 (https=) |
| JP (2) | JP7542439B2 (https=) |
| KR (1) | KR20200130395A (https=) |
| CN (1) | CN112105649B (https=) |
| AU (1) | AU2019231315A1 (https=) |
| CA (1) | CA3092993A1 (https=) |
| IL (1) | IL277181A (https=) |
| SG (1) | SG11202008568WA (https=) |
| WO (1) | WO2019173837A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3080109A1 (en) * | 2017-11-03 | 2019-05-09 | Sorrento Therapeutics, Inc. | Cd38-directed chimeric antigen receptor constructs |
| CA3103114A1 (en) * | 2018-06-20 | 2019-12-26 | Sorrento Therapeutics, Inc. | Variant antibody that binds cd38 |
| CN113825834A (zh) | 2019-03-11 | 2021-12-21 | 索伦托药业有限公司 | 使用rna引导的核酸内切酶进行dna构建体整合的改进工艺 |
| JP2022546577A (ja) * | 2019-09-05 | 2022-11-04 | ソレント・セラピューティクス・インコーポレイテッド | Ｂｃｍａと結合する二量体抗原受容体（ｄａｒ） |
| JP2023516595A (ja) * | 2020-02-27 | 2023-04-20 | ソレント・セラピューティクス・インコーポレイテッド | Ｃｄ２０を結合する二量体抗原受容体（ｄａｒ） |
| EP4139345A1 (en) * | 2020-04-24 | 2023-03-01 | Sorrento Therapeutics, Inc. | Memory dimeric antigen receptors |
| WO2022015956A1 (en) | 2020-07-15 | 2022-01-20 | Sorrento Therapeutics, Inc. | Improved process for dna integration using rna-guided endonucleases |
| KR102598598B1 (ko) | 2020-10-08 | 2023-11-07 | 엘티소재주식회사 | 헤테로고리 화합물, 이를 포함하는 유기 발광 소자, 이의 제조 방법 및 유기 발광 소자의 유기물층용 조성물 |
| CN116601174A (zh) * | 2020-10-12 | 2023-08-15 | 索伦托药业有限公司 | Cd19定向的嵌合抗原受体构建体 |
| KR20230153529A (ko) * | 2021-02-19 | 2023-11-06 | 프리트 엠. 쇼드하리 | 다양한 면역세포를 위한 단일사슬 및 다중사슬 합성 항원 수용체 |
| CN112662631B (zh) * | 2021-03-16 | 2021-06-29 | 合源生物科技(天津)有限公司 | 一种car-t细胞灌流培养方法 |
| EP4326292A4 (en) * | 2021-04-23 | 2025-03-26 | Vivasor, Inc. | Dimeric antigen receptors (dars) that bind gd2 |
| KR20240125982A (ko) * | 2021-12-24 | 2024-08-20 | 에테하 쭈리히 | 세포-기반 면역요법을 위한 다중 사슬 항원-특이적 수용체 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| WO2013044225A1 (en) * | 2011-09-22 | 2013-03-28 | The Trustees Of The University Of Pennsylvania | A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens |
| US9951144B2 (en) * | 2015-04-08 | 2018-04-24 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD38 |
| WO2016168493A1 (en) | 2015-04-15 | 2016-10-20 | Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center | Hepatic arterial infusion of car-t cells |
| EP3842448A1 (en) | 2015-05-15 | 2021-06-30 | City of Hope | Chimeric antigen receptor compositions |
| MX2018004721A (es) * | 2015-10-23 | 2018-07-06 | Eureka Therapeutics Inc | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. |
| JP2018537076A (ja) * | 2015-10-23 | 2018-12-20 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | プログラム可能な普遍的細胞受容体およびその使用法 |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| US11116834B2 (en) * | 2016-10-19 | 2021-09-14 | City Of Hope | Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy |
| CA3080109A1 (en) | 2017-11-03 | 2019-05-09 | Sorrento Therapeutics, Inc. | Cd38-directed chimeric antigen receptor constructs |
| EP3729081B1 (en) | 2017-12-21 | 2025-02-19 | F. Hoffmann-La Roche AG | Car-t cell assay for specificity test of novel antigen binding moieties |
| EP3775902B1 (en) | 2018-04-04 | 2023-02-22 | F. Hoffmann-La Roche AG | Diagnostic assays to detect tumor antigens in cancer patients |
| EP3775883A1 (en) | 2018-04-04 | 2021-02-17 | F. Hoffmann-La Roche AG | Diagnostic assays to detect tumor antigens in cancer patients |
-
2019
- 2019-03-11 AU AU2019231315A patent/AU2019231315A1/en not_active Abandoned
- 2019-03-11 KR KR1020207028896A patent/KR20200130395A/ko not_active Ceased
- 2019-03-11 CA CA3092993A patent/CA3092993A1/en active Pending
- 2019-03-11 EP EP19764893.4A patent/EP3762430A4/en not_active Withdrawn
- 2019-03-11 SG SG11202008568WA patent/SG11202008568WA/en unknown
- 2019-03-11 WO PCT/US2019/021681 patent/WO2019173837A1/en not_active Ceased
- 2019-03-11 CN CN201980031146.3A patent/CN112105649B/zh active Active
- 2019-03-11 JP JP2020546854A patent/JP7542439B2/ja active Active
-
2020
- 2020-09-04 US US17/013,359 patent/US12180294B2/en active Active
- 2020-09-07 IL IL277181A patent/IL277181A/en unknown
-
2023
- 2023-10-04 JP JP2023172758A patent/JP2023168545A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021515558A5 (https=) | ||
| JP2025065142A5 (https=) | ||
| Ellwanger et al. | Redirected optimized cell killing (ROCK®): a highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity | |
| JP6633081B2 (ja) | 細胞 | |
| Kudo et al. | T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing | |
| JP2019537433A5 (https=) | ||
| Davila et al. | Biology and clinical application of CAR T cells for B cell malignancies | |
| JP2020511136A5 (https=) | ||
| JP7702143B2 (ja) | 免疫細胞によって合成され、分泌される機能的バインダー | |
| JP2021191265A (ja) | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ−ａ３を認識するｔ細胞受容体 | |
| CN110461335A (zh) | 用于治疗bcma相关癌症和自身免疫性失调的联合疗法 | |
| JP2021525524A5 (https=) | ||
| Peipp et al. | Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer | |
| FI4324851T3 (fi) | BCMA-spesifisiä kimeerisiä antigeenireseptoreita ja niiden käyttöjä | |
| JP2018518939A5 (https=) | ||
| JP2018508219A5 (https=) | ||
| JP2016514462A5 (https=) | ||
| CN107849112A (zh) | 嵌合抗原受体(car)、组合物及其使用方法 | |
| Murad et al. | Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies | |
| JP2022513460A5 (https=) | ||
| US20190177398A1 (en) | Chimeric antigen receptors having gitr intracellular domain as co-stimulatory domain | |
| BR112021007995A2 (pt) | molécula de anticorpo antagonista, sequência de nucleotídeos isolada, plasmídeo, vírus, célula, uso de uma molécula de anticorpo, composição farmacêutica, método para tratar câncer ou uma infecção causada por um patógeno intracelular em um paciente | |
| JP2026500718A (ja) | Ｂ７－ｈ３を標的とする抗体または抗体断片、およびキメラ抗原受容体免疫細胞療法の分野におけるその使用 | |
| JP2020532969A5 (https=) | ||
| JP2022525318A5 (https=) |